pharmaphorum

SEPTEMBER 22, 2022

Read on to find out about unlocking the potential of connected commercialisation solutions, what HCPs want from post-pandemic communication, achieving launch excellence in oncology and much more. Achieving launch excellence in oncology. A successful launch in the oncology space is not guaranteed; it is strategically planned and earned.

Gene Therapy 52

Gene Therapy Marketing Gene Sales 52

pharmaphorum

DECEMBER 2, 2022

Read on for key stories from this year’s Frontiers Health conference in Italy, unlocking the promise of patient support programmes in oncology, supercharging communications with modular content, and much more. Unlocking the promise of patient support programmes in oncology. Read Deep Dive: Digital Health 2022 in full.

Pharma Companies 52

Pharma Companies Vaccination Vaccine Marketing 52

pharmaphorum

JULY 12, 2021

The pandemic forced massive changes to oncology sites to ensure patient safety and research continuity – but we must recalibrate and work with sites to understand the value proposition of the technologies and methodologies adopted, says Syneos Health’s Angela Hirst.

Nurses 52

Nurses Clinical Research Trials Research 52

pharmaphorum

OCTOBER 6, 2022

Many of these challenges are exacerbated in oncology, where the treatment landscape rapidly evolves with novel mechanisms of actions (e.g., Strategic planning and early investments in HCP and patient education are critical success factors for small and emerging companies launching oncology products.

Clinical Trials 52

Clinical Trials Clinical Trials Antibody Production 52

pharmaphorum

MAY 6, 2022

Combination pricing: access to the future of oncology treatment. Read Deep Dive: Market Access in full. pharmaphorum’s digital magazine Deep Dive provides objective, issue-driven views, analysis, high-level interviews and unique research for pharmaceutical companies, biotech firms and the wider healthcare sector.

Marketing 52

Marketing Life Science Regulation Development 52

pharmaphorum

APRIL 30, 2021

Blogger Chris Aldred and Joe Delahunty from Ascensia discuss what the industry often gets wrong in its patient engagement. • Read the latest issue Deep Dive: Market Access 2021 in full. Subscribe to future issues of Deep Dive. The post Deep Dive: Market Access appeared first on.

Marketing 98

Marketing Sales Regulation Drugs 98

pharmaphorum

AUGUST 4, 2022

Over the past two decades, innovative research efforts, such as the Human Genome Project and 100,000 Genomes Project, have vastly expanded our understanding of the human genome and its role in driving research and development in oncology. The post Realising the promise of genomic testing across oncology appeared first on.

Genome 52

Genome Genomics Genome Project DNA 52

pharmaphorum

JULY 23, 2021

If ASCO 2021 proves anything, it’s that the explosion in immuno-oncology therapies over the last few years shows no signs of slowing down. The post Digital tools key to immuno-oncology’s future: report appeared first on. As the field becomes more crowded, digital tools may be critical for improving outcomes, says a new whitepaper.

Doctors 52

Doctors Doctor Medicine Development 52

pharmaphorum

DECEMBER 14, 2020

As this issue’s title suggests, patient centricity is about more than just talking points and marketing strategies – it requires companies to truly listen to, engage with and partner with the patients they serve, and in putting this month’s Deep Dive together it’s been great to see that so many pharma firms are now taking this to heart.

Clinical Trials 75

Clinical Trials Clinical Trials Trials Marketing 75

Drug Discovery World

DECEMBER 12, 2022

Biometrics contract research organisation (CRO) Phastar has joined Lean Life Science’s Oncology Development Programme (ODP2). . The targeted programme aims to identify and accelerate novel oncology innovations into commercially-attractive assets by offering support to academics and early-stage companies. .

Development 52

Development Drugs Pharma Companies Clinical Trials 52

pharmaphorum

JULY 21, 2021

COVID’s impact on cancer care and oncology research has been devastating, but the pandemic has also opened up opportunities to take learnings and create long-lasting change in research, practice and education, says Lucid’s Frances O’Connor. The post Oncology and a year of COVID: lessons for the future appeared first on.

Pharma Companies 52

Pharma Companies Research Clinical Research Trials 52

pharmaphorum

DECEMBER 14, 2022

Fuelled by technological advancements, patient support programmes (PSPs) – also known as patient assistant programmes – are gaining attention as a potential way to deliver continual care for oncology patients. The post Unlocking the promise of patient support programmes in oncology appeared first on.

Genome 52

Genome Genomics Drugs 52

pharmaphorum

SEPTEMBER 17, 2020

Patient simulations have been a key tool for educating physicians for decades – and now cutting-edge tech is helping them become more impactful than ever. • Read the latest issue Deep Dive: Communications 2020 in full. Subscribe to future issues of Deep Dive. The post Deep Dive: Communications 2020 appeared first on.

Marketing 52

Marketing Sales Research Development 52

pharmaphorum

JULY 19, 2021

“Because of that, companies are under a lot of pressure to get a return on investment from these meetings.”. • Read the full article in pharmaphorum’s Deep Dive digital magazine. The post How hybrid virtual engagement is accelerating oncology communication appeared first on.

Compliance 52

Compliance Development 52

pharmaphorum

JUNE 7, 2022

But the issue around pricing and reimbursement of combination therapies within the current healthcare system isn’t something I – or the pharmaceutical industry – can resolve in isolation. • Read the full article in pharmaphorum’s Deep Dive digital magazine.

Clinical Trials 52

Clinical Trials Clinical Trials Marketing Medicine 52

pharmaphorum

JANUARY 18, 2022

With so many active research areas in oncology, patients and their loved ones can easily be overwhelmed by information and not know where to direct their attention. As Rebecca Goldstein says, “The fact is we have a lot of really active drugs in cancer right now. The post Targeted agents and immunotherapies appeared first on.

Development 98

Development Drugs Research 98

pharmaphorum

JULY 28, 2021

“As research in the area has grown, we do see more discussions and participate with various organizations on the work around defining standards – but there are still gaps.”. • Read the full article in pharmaphorum’s Deep Dive digital magazine.

Gene 52

Gene Gene Therapy Trials Clinical Trials 52

pharmaphorum

FEBRUARY 26, 2021

From animal processing, to cell therapy and AI, Tim Mullane, president, and chief operating officer tells pharmaphorum how FUJIFILM Irvine Scientific has evolved to become one of the top manufacturers of cell culture media. • Read the latest issue Deep Dive: Research and Development 2021 in full.

Development 58

Development Research Pharma Companies Vaccination 58

pharmaphorum

NOVEMBER 2, 2020

Most of the digital health experts we spoke to for this issue of Deep Dive made one thing clear – no one can really say what the future holds for digital tech in the pharma and healthcare industries. Subscribe to future issues of Deep Dive. The post Deep Dive: Digital Health Innovation 2020 appeared first on.

Sales 58

Sales Clinical Trials Clinical Trials Marketing 58

pharmaphorum

JULY 26, 2021

Imagine you are a pharma executive working in oncology R&D. Evidence shows that, despite historical success, the oncology R&D pipeline is unsustainable, not only becoming increasingly difficult and costly, but also fast approaching relative stagnation. The landscape is rapidly becoming more competitive and overcrowded.

Regulation 52

Regulation Trials Marketing Drugs 52

XTalks

JULY 21, 2023

These members now have access to the advanced Iris platform, offering specialized mental health care tailored for oncology patients, 24×7 symptom management and essential nutritional support. All of these services are available at no cost through participating health plans.

Nurses 98

Nurses Doctors Doctor Clinical Trials 98

Delveinsight

AUGUST 25, 2021

The key focus areas under the pharmaceuticals are Immunology, Infectious Diseases, Neuroscience, Oncology, Cardiovascular and Metabolism, and Pulmonary Hypertension. Deep dive into J&J portfolio based on revenue shares in 2020. Deep dive into Roche portfolio based on revenue shares in 2020. Around USD 44.5

Vaccination 98

Vaccination Vaccine Sales Drugs 98

pharmaphorum

MARCH 21, 2022

Designed for experts working directly on myeloid-directed therapies, and those in adjacent immuno-oncology fields, from cell therapy to checkpoint and engager development.

Clinical Development 52

Clinical Development Development 52

pharmaphorum

APRIL 20, 2021

Join global investors to: Leverage the knowledge gained from the current EGFR-TKI successes to implement it into strategies for improvement, best application strategies and potential combination partners with AstraZeneca, Puma Biotechnology, Cullinan Oncology and Takeda. View the event guide now for more details!

Development 52

Development Drugs Clinical Trials Clinical Trials 52

pharmaphorum

NOVEMBER 22, 2021

Celebrating 20 years of FDA approval and high efficacy profiles, kinase inhibitors have changed the face of oncology treatment. Turbocharge the Development of the Best-In-Class Kinase Inhibitor Products, to Enhance Specificity, Overcome Resistance to Deliver Safe & Durable Clinical Responses.

FDA Approval 52

FDA Approval Development Drugs Clinical Development 52

VirTrial

JANUARY 2, 2024

Oncology COA Measurement Strategy & Focus on PROMs Oncology will continue to be an area of concentrated focus in clinical research. Emerging biopharma can utilize our Unified Platform for any trial and any phase.

Clinical Research 52

Clinical Research Research Clinical Trials Clinical Trials 52

pharmaphorum

JUNE 8, 2021

Speaking to us after his appearance on the Withers podcast Talking Success , Mei says he founded Antengene – after leading oncology drug development at J&J, Novartis and Celgene– to address this need for innovative drugs with best-in-class and/or first-in-class potential targeting medical needs specific to APAC. Unmet needs in cancer.

Marketing 105

Marketing Drugs Regulation Development 105

Drug Discovery World

JULY 3, 2023

From June 20-22, 2023, Cambridge Healthtech Institute hosted the seventh annual Immuno-Oncology Summit Europe in London. The post Immuno-Oncology Summit Europe 2023: Programme highlights appeared first on Drug Discovery World (DDW).

Antibody 52

Antibody In-Vitro Engineer In-Vivo 52

pharmaphorum

MAY 10, 2021

This article appears in full in this month’s Deep Dive digital magazine on Market Access. More granular data from the US demonstrates a wide variation across specialities, with oncology particularly lagging behind in total promotional activity.

Pharma Companies 89

Pharma Companies Marketing Research 89

XTalks

FEBRUARY 22, 2024

“We are encouraged by the FDA’s acceptance of the BLA as we endeavor to make datopotamab deruxtecan the first TROP2-directed ADC approved to treat patients with nonsquamous NSCLC after disease progression on prior systemic therapy,” said Susan Galbraith, executive VP of Oncology R&D at AstraZeneca, in the company’s news release.

Antibody 59

Antibody Clinical Trials Clinical Trials Trials 59

XTalks

MARCH 28, 2024

Immunotherapy Immunotherapy has been and continues to be a revolutionary form of treatment in oncology, including for CRC. The five-year relative survival rate for CRC increased from 50 percent in the mid-1970s to 65 percent between 2012 and 2018. An overview of some of the most promising developments in CRC treatment is provided below.

Gene Editing 59

Gene Editing Life Science Clinical Trials Clinical Trials 59

XTalks

NOVEMBER 29, 2023

Dr. Cameron points out that while this avenue of research isn’t the primary focus of BIG, numerous groups worldwide are diving deep into it. But there’s a challenge: most breast cancer patients, understandably, do not have prior knowledge of oncology trials. Their journey often starts with a diagnosis that can be overwhelming.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Research 52

Camargo

APRIL 20, 2021

As our knowledge of oncology science advances and expands, a growing number of malignancy types and subtypes are constantly being identified, breaking down target patient populations into ever-smaller fractions. Oncology therapies typically have a comparatively shorter lab-to-clinic turnaround time than therapeutics targeting other diseases.

Development 137

Development Genotoxicity Production Drugs 137

pharmaphorum

JULY 14, 2021

“The next frontier is really around digital solutions that cause drug-like changes in the body; so far, these are typically seen in CNS – the video game Akili for ADHD being one example.”. • Read the full article in pharmaphorum’s Deep Dive digital magazine.

Development 58

Development Drugs 58

pharmaphorum

AUGUST 2, 2021

“They’re missing the buzz of having the institute full, and the resulting creative interaction that can spark new ideas.”. • Read the full article in pharmaphorum’s Deep Dive digital magazine. The post Cancer research faces uncertain post-COVID landscape appeared first on.

Research 52

Research Scientist Clinical Trials Clinical Trials 52

pharmaphorum

JULY 30, 2021

How wrong we were. • Read the full article in pharmaphorum’s Deep Dive digital magazine. Past experience led most of us to place an optimistic scenario at 12 months, but more realistically 18 months. The post Surprise pandemic lessons for pharma appeared first on.

Life Science 52

Life Science Vaccination Vaccine Development 52

XTalks

SEPTEMBER 12, 2023

Listeners can detect the genuine passion in the voices of our podcasters and interviewees, revealing their deep expertise. These stories can range from successful drug discoveries and clinical trial breakthroughs to regulatory approvals and real professional experiences.

Life Science 105

Life Science Branding Clinical Trials Clinical Trials 105